KDR and non-small cell lung carcinoma: APSNM achieves precise tumor targeting and dual PD-L1 inhibition (intracellularly via downregulation of the p-VEGFR2/p-JAK2/p-STAT3 pathway, intracellularly via p-VEGFR2/p-JAK2/p-STAT3 pathway downregulation, extracellularly via antibody blockade), while simultaneously employing sonodynamic therapy (SDT) to generate reactive oxygen species (ROS) and enhance antitumor immunity, significantly improving treatment outcomes for NSCLC.